MANAGEMENT OF EPITHELIAL OVARIAN NEOPLASMS USING A PLATINUM-BASED REGIMEN - A 10-YEAR EXPERIENCE

One-hundred and twenty-four patients with primary advanced (n = 103) and recurrent (n = 21) ovarian carcinoma completed a course of platinum-based chemotherapy (cyclophosphamide/doxorubicin/cisplatin or cyclophosphamide/cisplatin) or developed progressive disease while on therapy and were evaluated. All patients were treated between August 1, 1977 and December 31, 1987. The 5-year survival for patients with primary disease was 27% for stage III (n = 73) and 7% for stage IV (n = 30). The 5-year survival based on residual disease was 91% for microscopic disease (n = 13), 24% for disease <2 cm (n = 27), and 8% for disease ≥2 cm (n = 64). The 5-year survival for the patients treated with recurrent disease was 5% (n = 21). Borderline tumors have been excluded. Long-term toxicity, including cardiac toxicity, renal toxicity, and a 5% incidence of second primary tumors, is evaluated. © 1990.